Dr. Jasjit Dillon, MBBS, DDS, FDSRCS, FACS
Dr Jasjit (Jas) Kaur Dillon is Professor, Chief and Program Director of Oral and Maxillofacial Surgery at the University of Washington, Harborview Medical Center where she has a busy oncology, trauma and reconstructive practice. Her clinical training has been garnered from 5 countries – the UK, South Africa, Hong Kong, Vancouver BC and San Francisco. She obtained her dental degrees from the University of Newcastle Upon Tyne (BDS), the University of California San Francisco (DDS) and her medical degree from St Bartholomew’s School of Medicine, University of London (MBBS). She is a member of the Royal College of Surgeons of England (FDSRCS), the American College of Surgeons (FACS) and is a past examiner for the American Board of OMS. She the section editor in Pathology for the Journal of Oral & Maxillofacial Surgery. She has published over 75 scientific papers and book chapters and lectures nationally, and internationally. She is the recipient of two major grants studying medication related osteonecrosis of the jaws.
Dr. Bruce E Clurman, MD, PhD
Dr. Bruce Clurman is the executive vice president, chief scientific officer, and deputy director of Fred Hutch. He plays leading roles in developing and executing Fred Hutch’s research strategy and works with institutional leaders and partner institutions across the cancer center and adult oncology enterprise. Dr. Clurman holds the Rosput Reynolds Endowed Chair at Fred Hutch, where he is a Professor in the Translational Science and Therapeutics and Human Biology divisions. A medical oncologist specializing in bone marrow transplantation, Dr. Clurman is a Professor of Medicine at the University of Washington School of Medicine, where he also holds Adjunct Professor positions in the Departments of Laboratory Medicine and Pathology and Oral Health Sciences.
Dr. Clurman studies the molecular pathways that control cell division and their roles in the development and treatment of cancer. This work includes understanding how protein destruction by the ubiquitin–proteasome system controls normal and malignant cell proliferation. His work has focused on the cyclin-CDKs, proteins that drive cell division; the Fbw7 tumor suppressor, which targets a network of cancer-promoting proteins for destruction; and the Myc oncoprotein, which is central to many cancers. Ultimately, he seeks to understand how these pathways shape cancer development and progression, and to use this understanding to design new cancer therapies. An elected member of the Association of American Physicians and the American Society of Clinical Investigation, Dr. Clurman’s laboratory has been continuously funded by the National Cancer Institute.
Dr. Gulaiim Almatkyzy, PhD
Gulaiim “Gula” Almatkyzy is a Postdoctoral Scholar in the Department of Oral Health Sciences. Dr. Almatkyzy recently earned her PhD in Public Health from Oregon State University. She also received Master of Science in Global Health degree from the University of Notre Dame and Bachelor of Science in Biological Sciences degree from Nazarbayev University in Astana, Kazakhstan.
Dr. Almatkyzy is a social and behavioral health researcher with an interest in preventing chronic diseases, addressing cancer health disparities, and improving vaccination uptake in marginalized and underserved communities. In the School of Dentistry, she works on research projects to reduce fluoride hesitancy and improve oral public health in Alaska Native communities.